Expert review of vaccines
-
Expert review of vaccines · Jan 2009
Review Comparative StudyIMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.
Smallpox vaccines based on replicating vaccinia virus are known to elicit rare yet serious adverse events, particularly in human populations with immune deficiency, atopic dermatitis and at the extremes of age. A vaccine that induces protective immune responses equivalent to first-generation smallpox vaccines while reducing the risk for severe adverse events is critical for a national stockpile of smallpox vaccines. ⋯ IMVAMUNE has been administered to more than 1900 human subjects to date, including high-risk populations (e.g., people diagnosed with atopic dermatitis or infected with HIV) in which standard replicating vaccines are contraindicated. We review the Phase I clinical trial safety profile and immune responses and compare them with other smallpox vaccines, including ACAM2000 and Dryvax.
-
Expert review of vaccines · Jan 2009
ReviewOral polio vaccines and their role in polio eradication in India.
Although the oral polio vaccine has reduced the incidence of polio in India, the current polio scenario indicates that oral polio vaccine cannot eradicate polio from Uttar Pradesh and Bihar, two states that have approximately 32% of the total Indian population and report more than 96% of polio cases that occur in India. Poor response to oral polio vaccine by some children from these two states could be due to genetic factors. Thus, for polio eradication in India, inactivated polio vaccine is needed.